Harbert institute for innovation and entrepreneurship
UAB startup NuVasc is advancing precision medicine for brain arteriovenous malformations with a novel liquid biopsy that identifies genetic mutations driving AVMs, paving the way for targeted therapies and improved patient outcomes.
LifeNuclear aims to make radiopharmaceutical therapy safer and easier for patients with the TheraGuide platform. Plans include pilot evaluations and clinical partnerships.
UAB startup TIXiMED advances TIX100, a novel oral Type 1 diabetes therapy, into Phase 1b clinical testing. The TXNIP-targeting drug aims to protect insulin-producing beta cells and address disease progression beyond blood sugar management.
The TeaCha™ app will provide a space where teachers can share experiences, exchange strategies and support one another.
The Cure Innovation Index ranked UAB among top‑tier U.S. biomedical research institutions that convert discovery into therapies, companies and measurable health outcomes.
UAB researchers have secured a patent for a novel lens design that could slow myopia progression in children, translating decades of vision science research into potential clinical therapies.
PreciPS identifies frontline frustrations before providing operational solutions in patient care.
Recent innovations include a noninvasive external urine collection device, a system designed to simplify how clinicians manage fluid balance in critically ill patients, an ergonomic assist device for ureteroscopy and new ways to prevent kidney stones.
UAB researchers are developing a new at-home cervical cancer screening device aimed at increasing access to screening and improving early detection.
UAB scientists discovered an oral drug stopped weight rebound after discontinuation or cessation of GLP‑1 treatment in preclinical studies, opening the door to a new approach for maintaining weight loss.
Functional neurological disorder, an often-misunderstood condition, affects brain-body communication, causing involuntary seizures, movement difficulties and speech problems.
UAB’s first nonprofit startup, Dream a Little Dream, is improving global cystic fibrosis care by empowering medical teams with cost-effective tools and training.
The Blazer Bridge Fund encourages discovery among the UAB community by providing financial support to innovative ideas and inventions.
Michael Niederweis, Ph.D., and Cynthia Owsley, Ph.D., who collectively hold 23 patents, have been recognized for approaches to DNA sequencing and detection of impaired dark adaptation, respectively.
Rothenberg’s innovative, FDA-approved technology will improve cardiac health through enhanced treatment and prevention.
Yager’s journey as a Blazer is filled with institutional, national and international recognition; her most recent milestone is her unique patented catalytic reactor for NASA missions that has multiple applications in various other industries.
Blazer Bridge Fund provides financial support to innovative ideas and inventions by the UAB community, encouraging advanced discovery.
This live biotherapeutic product, tested in mouse models, shows promise in addressing common pathways of lung disease progression.
The novel drug TIX100 functions differently from any approved diabetes drug to promote proper islet cell function.
Fobian developed Retraining and Control Therapy, or ReACT, to help patients with functional neurological disorder, or FND, which affects an estimated 300,000 Americans.